Research Paper for IBSACOL


IBSACOL contains Meracol, a trademarked and patented plant based fatty acid ester.

The following study set out to demonstrate the relationship between inflammation and IBS then to investigate the application of Meracol in controlling the inflammation.

Dr. T.D. Meakin B.Sc. M.D. FRNZCGP*
Auckland, New Zealand 
I was co-investigator in a double-blinded trial using Meracol (the active ingredient in IBSACOL) at Wellington Hospital, New Zealand in 1998-99.
During the trial, a dosage of 26 capsules of Meracol was taken daily, after a four-week period this was reduced to 16 capsules per day.
During the trial, side effects were monitored as instructed by SCOTT. The two side effects that were recorded in the active treatment group were constipation (2/27) and headache (3/27). These were transient and, with adequate hydration, resolved spontaneously.
Bloods were taken at Week 1, at Week 3 and at Week 5
Included in this profile were:
Hb Cr 
MCV Urea 
wbc Albumin
Neutrophils Protein
Lymphocytes ALP
Monocytes ALT
Eosinophils GGT
Basophils AST
Na Bilirubin
K Fasting lipids 
From these tests, one can conclude that Meracol has a good safety profile as all of these blood tests remained unchanged during the trial with the 27 active patients treated with Meracol. The only exception was a slight increase in HDL or good cholesterol levels.
No adverse reactions or drug interactions were reported. Overall I was impressed with the limited side-effect profile that Meracol produced, even at a relatively high dose.


Published third party research demonstrates the relationship between inflammation and IBS, and the connection between low levels of the anti-inflammatory cytokine IL 10 with IBS and IBD.[i]
• Preliminary research indicates Meracol is a modulator of the anti-inflammatory cytokine IL-10, increasing low levels to normal when necessary and maintaining normal levels without further increase. A pilot research study has demonstrated that Meracol can produce a 10-fold increase in IL-10 within a 21 day period.[ii]
• The observed immune responses correlate to improved symptomatology in clinical observation.


• Chadwick et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology; 122(7): 2078-80, 2002C [abstract]
• S Schreiber. Interleukin-10 in the intestine (commentary). GUT;41:274-275, 1997 [abstract]
• RC Spiller. Neuropathology of IBS? Gastroenterology: 2144-7, 2002 [abstract]
• Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?. Gut;52(1):91-3, 2003 [abstract] 
• Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell;75(2):263-74, 1993 [abstract] 
• S Nikolaus, J Bauditz, P Gionchetti, C Witt, H Lochs, S Schreibera. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. GUT 42:470-476, 1998 [abstract] 
• L Steidler. New Cytokine treatment for inflammatory bowel disease. Science 289: 1352-4, 2000 
• K. Asadullah, W. Sterry and H. D. Volk. Interleukin-10 Therapy—Review of a New Approach. Pharmacol Rev 55:241-269, 2003 [abstract]
[ii] Immune effects of Meracol: Pilot data analysis – Professor Jeff Keelan, Liggins Institute, University of Auckland, New Zealand


* After observing the effects of IBSACOL in patients with IBS Dr. Meakin has become a shareholder of Meracol Corporation’s parent company.


Shop online